Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Neoplasms, Triple-Negative”

1,411 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,411 results

Large-scale testing (Phase 3)Ended earlyNCT04335006
What this trial is testing

Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04331067
What this trial is testing

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Washington University School of Medicine 15
Early research (Phase 1)Ended earlyNCT03742349
What this trial is testing

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Novartis Pharmaceuticals 64
Testing effectiveness (Phase 2)UnknownNCT03805399
What this trial is testing

FUSCC Refractory TNBC Umbrella (FUTURE)

Who this might be right for
Triple-negative Breast Cancer
Fudan University 140
Early research (Phase 1)Ended earlyNCT01876251
What this trial is testing

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Pfizer 30
Large-scale testing (Phase 3)Looking for participantsNCT05862064
What this trial is testing

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 606
Testing effectiveness (Phase 2)Study completedNCT02422498
What this trial is testing

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Who this might be right for
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center 49
Not applicableUnknownNCT04145947
What this trial is testing

Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients

Who this might be right for
Triple Negative Breast Cancer
Peking Union Medical College Hospital 200
Testing effectiveness (Phase 2)UnknownNCT03961698
What this trial is testing

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Who this might be right for
Breast CancerRenal Cell Carcinoma
Infinity Pharmaceuticals, Inc. 91
Testing effectiveness (Phase 2)Looking for participantsNCT06238921
What this trial is testing

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerTriple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339176
What this trial is testing

Intratumoral N17350 in Advanced Solid Tumors

Who this might be right for
Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more
Onchilles Pharma Inc 275
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05806385
What this trial is testing

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers

Who this might be right for
Triple Negative Breast Cancer
Texas Tech University Health Sciences Center 36
Testing effectiveness (Phase 2)Ended earlyNCT05219578
What this trial is testing

RTX-224 Monotherapy in Patients With Solid Tumors

Who this might be right for
Non Small Cell Lung CancerCutaneous MelanomaHead and Neck Squamous Cell Carcinoma+2 more
Rubius Therapeutics 7
Early research (Phase 1)Study completedNCT03205176
What this trial is testing

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Who this might be right for
Malignant Solid TumorsLymphomaOvarian Cancer+3 more
AstraZeneca 49
Large-scale testing (Phase 3)Looking for participantsNCT06393374
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Who this might be right for
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC 1,530
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Active Not RecruitingNCT06889688
What this trial is testing

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer Stage IV
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 246
Testing effectiveness (Phase 2)Study completedNCT03316586
What this trial is testing

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 18
Early research (Phase 1)Looking for participantsNCT04485013
What this trial is testing

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Who this might be right for
Cancer
Tizona Therapeutics, Inc 240
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Load More Results